Evidence map›Paper›PMID 34540345›Full record

ArticleAmerican journal of blood research2021

Ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the "RTL" (regional Tuscan lymphoma network).

Emanuele Cencini, Bianca Mecacci, Francesca Morelli, Francesco Ghio, Ilaria Romano, Silvia Birtolo, Federico Simonetti, Valentina Zoi, Sabrina Moretti, Emanuela Sant'Antonio and 6 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of blood research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

Emanuele CenciniUnit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena Siena, Italy.
Bianca MecacciUnit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena Siena, Italy.
Francesca MorelliLymphoma Unit, Hematology Department, Careggi Hospital and University of Florence Florence, Italy.
Francesco GhioUnit of Hematology, Azienda Ospedaliera Universitaria Pisana and University of Pisa Pisa, Italy.
Ilaria RomanoLymphoma Unit, Hematology Department, Careggi Hospital and University of Florence Florence, Italy.
Silvia BirtoloSOS Oncoematologia Pistoia e Pescia Italy.
Federico SimonettiUOC Ematologia Dipartimentale ATNO, Ospedale Versilia Lido di Camaiore, Italy.
Valentina ZoiUOS Oncoematologia Usl Toscana Sud Est Arezzo, Italy.
Sabrina MorettiSOC Ematologia Clinica e Oncoematologia Firenze, Italy.
Emanuela Sant'AntonioUOC Ematologia Aziendale, Azienda USL Toscana Nordovest, Ospedale S. Luca Lucca, Italy.
Annarosa CuccaroUOC Ematologia Aziendale, Azienda USL Toscana Nordovest, Spedali Riuniti Livorno, Italy.
Simone SantiniSOS Oncoematologia, Ospedale S. Stefano Prato, Italy.
Sofia KovalchukLymphoma Unit, Hematology Department, Careggi Hospital and University of Florence Florence, Italy.
Sara GalimbertiUnit of Hematology, Azienda Ospedaliera Universitaria Pisana and University of Pisa Pisa, Italy.
Monica BocchiaUnit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena Siena, Italy.
Alberto FabbriUnit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena Siena, Italy.
Azienda Ospedaliera Universitaria Senese · ITAzienda Ospedaliero-Universitaria Careggi · ITAzienda Ospedaliera Universitaria Pisana · ITAzienda Usl Toscana Centro · ITAssociazione Italiana Ematologia Oncologia Pediatrica · ITAzienda Usl 8 Arezzo · ITFondazione Cassa di Risparmio di Pistoia e Pescia · ITOspedale di Prato Santo Stefano · ITOspedale Versilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRelapsed or refractory (R/R) mantle-cell lymphoma (MCL) patients have a poor prognosis and their management is challenging, in absence of a golden standard as salvage treatment. Bruton's tyrosine kinase inhibitor ibrutinib represents an effective treatment for R/R MCL patients. We investigated ibrutinib efficacy and safety in daily clinical practice, together with factors that could predict disease outcome. PATIENTS AND

methodsWe retrospectively analyzed 69 consecutive R/R MCL patients managed in 10 Tuscan onco-hematological centers. The treatment regimen consisted of oral, continuous, single-agent ibrutinib, maximum dosage of 560 mg once per day, until disease progression.

resultsOverall response rate was 62.3%, with a CR rate of 39.1%. After a median follow-up of 15.6 months, 40/69 patients (58%) were alive, the main cause of death was progressive disease (PD, 22/69 cases, 31.9%). Median progression-free survival (PFS) and overall survival (OS) were 17 and 34.8 months. Inferior PFS was associated with >1 prior line of therapy and B symptoms. Ibrutinib refractoriness was associated with inferior OS, median OS after ibrutinib failure was only 5 months. DISCUSSION AND

conclusionIn this real-life setting ibrutinib treatment prolonged survival in R/R MCL patients, without unexpected adverse events. Patients receiving ibrutinib as 2

Indexed as

ibrutinibMantle cell lymphomaprognosissafetysurvival

Identifiers

PMID34540345
PMCPMC8446834
OpenAlexW3199272327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.